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Abstract
Background: 6-Shogaol is one of the major compounds in the ginger rhizome that may contribute
to its anti-inflammatory properties. Confirmation of this contribution was sought in this study in
Sprague- Dawley rats (200–250 g) treated with a single injection (0.5 ml of 1 mg/ml) of a
commercial preparation of complete Freund's Adjuvant (CFA) to induce monoarthritis in the right
knee over a period of 28 days. During this development of arthritis, each rat received a daily oral
dose of either peanut oil (0.2 ml-control) or 6-shogaol (6.2 mg/Kg in 0.2 ml peanut oil).
Results: Within 2 days of CFA injection, the control group produced maximum edematous
swelling of the knee that was sustained up to the end of the investigation period. But, in the 6-
shogaol treated group, significantly lower magnitudes of unsustained swelling of the knees (from
5.1 ± 0.2 mm to 1.0 ± 0.2 mm, p < 0.002, n = 6) were produced during the investigation period.
Unsustained swelling of the knees (from 3.2 ± 0.6 mm to 0.8 ± 1.1 mm, p < 0.00008, n = 6) was
also produced after 3 days of treatment with indomethacin (2 mg/Kg/day) as a standard anti-
inflammatory drug, but during the first 2 days of drug treatment swelling of the knees was
significantly larger (11.6 ± 2.0 mm, p < 0.0002, n = 6) than either the controls or the 6-shogaol
treated group of rats. This exaggerated effect in the early stage of indomethacin treatment was
inhibited by montelukast, a cysteinyl leukotriene receptor antagonist. Also, 6-shogaol and
indomethacin were most effective in reducing swelling of the knees on day 28 when the controls
still had maximum swelling. The effect of 6-shogaol compared to the controls was associated with
significantly lower concentration of soluble vascular cell adhesion molecule-1 (VCAM-1) in the
blood and infiltration of leukocytes, including lymphocytes and monocytes/macrophages, into the
synovial cavity of the knee. There was also preservation of the morphological integrity of the
cartilage lining the femur compared to damage to this tissue in the peanut oil treated control group
of rats.
Conclusion:  From these results, it is concluded that 6-shogaol reduced the inflammatory
response and protected the femoral cartilage from damage produced in a CFA monoarthritic
model of the knee joint of rats.
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Background
6-Shogaol (1-4-hydroxy-3-methoxyphenyl-4-decen-3-
one) is one of the major biologically active compounds
found in the rhizome of Zingiber officinale/ginger [1]. This
compound was previously reported to have antipyretic
and analgesic effects in addition to inhibitory effect on
lipoxygenase activity [2,3]. Its presence in ginger may also
contribute to the anti-inflammatory effects associated
with the use of powdered ginger [4,5]. To confirm this
contribution, 6-shogaol was used in this study as an iso-
lated single compound to determine whether it has anti-
inflammatory properties and to demonstrate these prop-
erties in an animal model of chronic inflammation.
Many of the animal models used in investigations of
chronic inflammation produce polyarthritis after injec-
tion of complete Freund's adjuvant (CFA) or other pro-
inflammatory agents at the base of the rat tail [6] or in a
single foot pad of the rat [7] or a single knee joint of the
rat [8]. The polyarthritis developed in these animal mod-
els was reported to be dose-dependent such that large
doses of the pro-inflammatory agent were more likely to
produce inflammation at multiple sites [9] including the
corresponding contralateral sites to the injection sites [8].
This type of symmetrical development of polyarthritis in
the animal models is similar to human rheumatoid arthri-
tis, osteoarthritis and psoriasis [8], but the mechanisms
underlying the inflammatory response at the contralateral
sites are still unclear. There is however, evidence of neuro-
logical involvement in the development of inflammation
at the contralateral site as reported in a review by Shenker
et al [8]. Substance P (SP) and calcitonin gene-related pep-
tide (CGRP) were identified as neuropeptides that may be
involved in development of contralateral inflammation
[8]. These are pro-inflammatory neuropeptides that
increase mobilization of leukocytes from the blood and
loss of fluid from the circulation (8). The mechanisms of
these effects at the contralateral sites may be different
from the mechanism induced by the pro-inflammatory
agent at the primary injection site. Consequently, experi-
mental data obtained in the polyarthritic model would be
complex and difficult to interpret.
To avoid this complexity and to minimise the influence of
contralateral inflammation, a monoarthritic model was
used to investigate the anti-inflammatory potential of 6-
shogaol. The inflammation produced in this monoar-
thritic model is localized at the site of induction and
according to Butler et al [10], it is stable for chronic stud-
ies. Our model was developed with the use of a low
potency commercial preparation of CFA (compared to
preparations made from basic ingredients by other inves-
tigators [6,11]) to induce chronic inflammation in the
knees of Sprague Dawley rats over a period of 28 days. The
mycobacterium content of CFA was reported in several
studies to be the inducing agent of chronic inflammation
through stimulation of the immune response [12-14]. The
resulting pathological features include swelling of the
joint due to edema, leukocyte migration into the joint and
various degrees of cartilage degradation [6,11,15]. Sfikakis
and Tsokos [16] reported that leukocyte migration was
facilitated by adhesion molecules in the blood. An exam-
ple of this type of molecule was identified as soluble vas-
cular cell adhesion molecule-1 (soluble VCAM-1), and it
was reported to be produced in increased concentration in
the blood of patients with chronic inflammatory diseases
such as rheumatoid arthritis [17-19].
These features of chronic inflammation were reproduced
in the CFA monoarthritic model used in this study and
they provided the basis for evaluating the anti-inflamma-
tory potential of 6-shogaol.
Results
Effect of 6-shogaol on edema production in CFA treated 
rats
In a control group of rats that received peanut oil (0.2 ml,
orally) daily for 28 days, a single injection of CFA (0.5 ml
of 1 mg/ml) in the synovial cavity of the right knee of each
rat produced swelling of the knee due to edema. Maxi-
mum swelling of the knee was reached within 2 days of
CFA injection and it was measured as a mean increase in
knee circumference of 6.7 ± 0.2 mm (fig. 1). This magni-
tude of swelling was maintained up to the end of the 28
day investigation period (fig. 1). A comparatively lower
magnitude of unsustained swelling was produced within
2 days of CFA injection in the 6-shogaol (6.2 mg/kg/day)
treated rats. Maximum swelling in this group of rats,
obtained after 2 doses of 6-shogaol, was measured as a
mean increase in knee circumference of 5.1 ± 0.2 mm
which was significantly lower (p < 0.0002, n = 6) than in
the control group, and it was progressively reduced after
day 2 to reach a minimum of 1.0 ± 0.2 mm on day 28 (fig.
1). Qualitatively similar progressive reduction in mean
increase in knee circumference from 3.2 ± 0.6 mm to 0.8
± 1.1 mm (p < 0.0008, n = 6) was produced after three
doses of the standard anti-inflammatory drug indometh-
acin (2 mg/kg/day). But at the beginning of the treatment,
indomethacin did not inhibit the swelling after 2 doses,
consequently the maximum swelling, measured as a mean
increase in knee circumference of 11.6 ± 2.0 mm was sig-
nificantly larger (p < 0.0002, n = 6) than in the control
and 6-shogaol treated group of rats (fig. 1). This exacerba-
tion of the edematous swelling by indomethacin on day 2
was reduced from 11.6 ± 2.0 mm to 5.0 ± 1.0 mm, when
equimolar montelukast (3.4 mg/Kg/day, orally), a cystei-
nyl leukotriene receptor antagonist, was given in combi-
nation with indomethacin from day zero to day three of
the treatment period.BMC Pharmacology 2006, 6:12 http://www.biomedcentral.com/1471-2210/6/12
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Effect of 6-shogaol on leukocyte infiltration into the 
synovial cavity of CFA treated rats
Total leukocyte concentration in the fluid of the synovial
cavity was determined on day 28 when 6-shogaol and
indomethacin was most effective in reducing swelling of
the knee due to edema production. Figure 2 shows that
total leukocyte count on this day in the 6-shogaol and
indomethacin treated groups of rats was significantly
lower (p < 0.001, p < 0.000001 (respectively), n = 6) than
the count in the peanut oil treated control group of rats in
which maximum swelling of the knee was still present.
Differential counts of the infiltrated leukocytes show (fig.
2) that the 6-shogaol treated group of rats also had signif-
icantly lower counts compared to the peanut oil controls
for lymphocytes (4.0 ± 0.2 × 103 versus 6.4 ± 0.3 × 103, p
< 0.002, n = 6) and monocytes/macrophages (6.2 ± 0.2 ×
103 versus 12.0 ± 0.7 × 103, p < 0.002, n = 6). Indometh-
acin treatment also resulted in significantly lower counts
(fig. 2) for lymphocytes (1.1 ± 0.03 × 103 versus 6.4 ± 0.3
× 103, p < 0.001, n = 6) and monocytes/macrophages (0.4
± 0.01 × 103 versus 12.0 ± 0.7 × 103, p < 0.001, n = 6).
Effect of 6-shogaol on VCAM-1 concentration in the blood 
of CFA treated rats
Soluble VCAM-1 concentration in the blood was deter-
mined on day 28 when 6-shogaol was most effective in
reducing swelling of the knee due to edema production.
In the peanut oil treated control group, 1.3 ± 0.1 ng/ml of
soluble VCAM-1 was detected in the blood compared to
0.3 ± 0.1 ng/ml detected in the blood of the 6-shogaol
treated group of rats (fig. 3). These concentrations of sol-
uble VCAM-1 are significantly different (p < 0.001, n = 6),
and it is interesting to note that the lower concentration of
soluble VCAM-1 in the 6-shogaol treated group of rats was
associated with significantly lower infiltration of leuko-
cytes (92 ± 2 × 103, p < 0.001, n = 6) into the synovial cav-
ity compared to the controls (300 ± 2 × 103). Also, the
relationship between these two variables showed a strong
positive correlation (r = 0.98, p < 0.0005, df = 10) in
which the magnitude of leukocyte infiltration was
dependent on the concentration of soluble VCAM-1 pro-
duced in the blood.
Effect of 6-shogaol on femoral cartilage morphology of 
CFA treated rats
After 28 days of exposure of the two groups of rats to a sin-
gle CFA injection in the synovial cavity of the knee of each
rat and daily oral doses of either peanut oil (control
group) or 6-shogaol, histological sections of the knee
joint were prepared. Figure 4 shows a representative histo-
logical section of the knee joint with significant cartilage
damage that was produced in the peanut oil treated con-
trol group of rats. But no such damage of the cartilage was
detected in the 6-shogaol treated group of rats (fig. 4). In
Graph showing the effects of daily administration of 6-shog- aol (6.2 mg/Kg/day), indomethacin (2 mg/Kg/day) and peanut  oil (0.2 ml/day-control) on total leukocyte numbers and dif- ferential counts of monocytes/macrophages and lymphocytes  in synovial fluid aspirated from rats with knee inflammation  induced by a single dose of CFA (0.5 ml of 1 mg/ml) in the  synovial cavity Figure 2
Graph showing the effects of daily administration of 6-shog-
aol (6.2 mg/Kg/day), indomethacin (2 mg/Kg/day) and peanut 
oil (0.2 ml/day-control) on total leukocyte numbers and dif-
ferential counts of monocytes/macrophages and lymphocytes 
in synovial fluid aspirated from rats with knee inflammation 
induced by a single dose of CFA (0.5 ml of 1 mg/ml) in the 
synovial cavity. Each bar represents the mean ± SEM value 
from 6 animals. Asterisks indicate values significantly different 
from the peanut oil control (* p < 0.002, ** p < 0.001, *** p < 
0.000001).
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Graph showing the effects of daily oral administration of 6-
shogaol (6.2 mg/Kg/day), indomethacin (2 mg/Kg/day) and 
peanut oil (0.2 ml/day-control) on the development (over 28 
days) of edematous swelling of the knee induced by a single 
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mals. Asterisks indicate values significantly different from the 
peanut oil control (* p ≤ 0.0002, ** p < 0.00008)
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fact, the treatment with 6-shogaol was associated with
preservation of the morphological integrity of the carti-
lage lining the femur as shown in the representative
micrograph (fig. 4).
Discussion
Within 2 days of injecting 0.5 ml (1 mg/ml) complete Fre-
und's adjuvant (CFA) into the synovial cavity of the right
knees of three groups of rats, localized edematous swell-
ing to a maximum magnitude was produced as the first
sign of inflammatory response. The volume of fluid
injected in the knee was discounted from this response by
using the knee circumference taken thirty minutes after
the injection as the baseline from which the magnitude of
edematous swelling was calculated. The time course of
maximum edema production after CFA injection was sim-
ilar to that observed in the study reported by Yu et al [11].
However, the maximum swelling produced in our study
was smaller. This difference in magnitude of the response
was most likely due to a difference in potency of the com-
mercial CFA preparation used in our study. Support for
this suggestion is based on our use of a larger amount
(500 μg) of the commercial CFA compared to the 250 μg
prepared and used by Yu et al [11] for induction of
monoarthritis in the knee. Also, in other studies with the
CFA model [8,9] amounts above 250 μg usually produce
polyarthritis which was not obtained in our study; there-
fore our commercial preparation must have been of a
lower potency.
During the initial phase of the inflammatory response,
swelling of the knee was greatest on day 2 in the
indomethacin treated group compared to the peanut oil
treated control group of rats. But, in the 6-shogaol treated
group of rats, the magnitude of swelling was significantly
lower compared to either of the preceding groups of rats.
This difference in the early response to indomethacin
treatment compared to its usual anti-inflammatory effect,
appeared to have resulted from increased production of
pro-inflammatory cysteinyl leukotrienes whose effect was
inhibited in this study by the receptor antagonist, monte-
lukast [22]. This pro-inflammatory effect was also
obtained with the use of other non-steroidal anti-inflam-
matory drugs (NSAIDs). Aspirin, for example, was
reported to increase the production of cysteinyl leukot-
rienes and precipitate an asthmatic attack in susceptible
subjects [23,24]. The underlying mechanism of the
NSAIDs effect was postulated as resulting from an increase
in production of leukotrienes from the common arachi-
donic acid substrate following inhibition of cyclooxygen-
ase and production of prostaglandins by aspirin and
indomethacin [23,25].
After the early inflammatory response on day 2,
indomethacin and 6-shogaol progressively reduced the
edematous swelling of the knee to a level close to the pre-
treatment value by day 28. In contrast, maximum swelling
of the knee in the peanut oil treated controls was main-
tained up to the end of the investigational period on day
28. These results suggest that in this model of inflamma-
tion, 6-shogaol (6.2 mg/Kg/day) reduced edematous
swelling of the knee with similar effectiveness as an equiv-
alent human daily dose of indomethacin (per Kg body
weight = 2–3 mg/day) [26], which is a standard anti-
inflammatory drug [26]. Note that although enterohe-
patic cycling was previously reported by Oberbauer et al
[27] as contributing to delayed onset of indomethacin
therapeutic effect, this action may have only contributed a
minor effect compared to the cysteinyl leukotriene
involvement in the early exaggeration of the CFA inflam-
matory response observed in our study.
The effectiveness of 6-shogaol and indomethacin in
reducing the CFA-induced edematous swelling of the knee
was associated with significant reduction of total leuko-
cyte migration as well as lymphocytes and monocytes/
macrophages migration from the blood into the synovial
cavity. These inflammatory cells are major contributors to
the initiation and maintenance of the immune response
[28,29], and their concentrations were significantly
greater in the peanut oil treated controls compared to
either the 6-shogaol or indomethacin treated group of rats
in this study. Regulation of migration of these cells from
the blood was reported to be facilitated by adhesive inter-
actions with the vascular endothelium [18]. Soluble vas-
cular cell adhesion molecule, type-1 (soluble VCAM-1)
was identified as a major mediator of the adhesive inter-
actions [19,30]. In our study, the 6-shogaol treated group
Bar graph showing the concentration of soluble VCAM-1 in  the blood of rats on day 28 after treatment with a single dose  of CFA (0.5 ml of 1 mg/ml) in the knee, and daily oral doses  (for 28 days) of 6-shogaol (6.2 mg/Kg/day) and peanut oil (0.2  ml/day-control) Figure 3
Bar graph showing the concentration of soluble VCAM-1 in 
the blood of rats on day 28 after treatment with a single dose 
of CFA (0.5 ml of 1 mg/ml) in the knee, and daily oral doses 
(for 28 days) of 6-shogaol (6.2 mg/Kg/day) and peanut oil (0.2 
ml/day-control). Each bar shows the mean ± SEM value from 
6 animals. Asterisk indicates value significantly different from 
the peanut oil control (* p < 0.001).
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of rats had significantly lower concentration of soluble
VCAM-1 in the blood and leukocyte infiltration into the
synovial cavity compared to the peanut oil treated control
group. The relationship of these two variables showed
strong positive correlation in which the magnitude of leu-
kocyte infiltration into the synovial cavity was dependent
on the concentration of soluble VCAM-1 produced in the
blood.
It is also interesting to note that whereas low infiltration
of inflammatory cells in the synovial cavity of the 6-shog-
aol treated rats was not associated with damage to the car-
tilage, greater infiltration of inflammatory cells obtained
in the peanut oil treated controls was associated with
damage to the cartilage in these rats. This type of damage
in human arthritic joints was previously reported to result
from cellular output of toxic agents such as nitric oxide
and its oxidizing product, peroxynitrite which was
detected by the presence of protein nitrotyrosine marker
in synovial tissues of rheumatoid and osteoarthritic
patients [31]. Free radicals were also reported to be
involved in producing damage to the arthritic joint. Exam-
ples include malondialdehyde (MDA) which was detected
in high concentration in the blood of arthritic patients
[32], and products of hydrogen peroxide (hydroxyl radical
and hypochlorous acid produced by enzymatic action of
myeloperoxidase) which were associated with adjuvant
arthritis in rats[6].
In a more recent study of extracts from two species of gin-
ger (Alpinia galanga and Zingiber officinale) on human syn-
oviocytes, the investigators reported that the extracts
decreased TNFα  induced production of macrophage
chemotactic factor (MCP-1) and interferon-γ activated
protein (IP-10) as well as their respective mRNA [33]. In
another study of crude and fractionated extracts of Zin-
giber officinale on monocyte production of TNFα  and
PGE2, the investigators reported that both the crude and
fractionated extracts reduced production of these agents.
However, although the shogaol-rich extract inhibited the
production of PGE2 from the cells, they had no effect on
the induction of COX-2 enzyme [34]. The implication of
Representative micrographs of histological sections (5 μm) of the knee joint Figure 4
Representative micrographs of histological sections (5 μm) of the knee joint: Panels A and B show damage of the articular car-
tilage lining the femur of a rat that was given a single dose of CFA (0.5 ml of 1 mg/ml) in the synovial cavity and daily oral dose 
(0.2 ml) of peanut oil for 28 days. A (Mag × 10), B (Mag × 20), scale bars = 20 μm, Arrows indicate areas of cartilage degrada-
tion. Panels C and D show the articular cartilage lining the femur of a rat that was given a single dose of CFA (0.5 ml of 1 mg/
ml) in the synovial cavity and daily oral dose (6.2 mg/Kg) of 6-shogaol for 28 days. C (Mag × 10), D (Mag × 20), scale bars = 20 
μm. Arrows indicate smooth articular cartilage surface and regular arrangement of chondrocytes in isogenous groups.
AB
CDBMC Pharmacology 2006, 6:12 http://www.biomedcentral.com/1471-2210/6/12
Page 6 of 8
(page number not for citation purposes)
these results is that compounds such as 6-shogaol derived
from ginger has the potential to inhibit the production of
tissue damaging agents such as TNFα as well as chemotac-
tic factors that would attract inflammatory cells to areas of
joint inflammation.
When these results obtained by Phan et al [33] and Lantz
et al [34] are considered together with our findings, there
is strong support for anti-inflammatory properties for 6-
shogaol and other compounds derived from ginger. 6-
Shogaol was particularly effective in our study in reducing
CFA induced chronic inflammation in the knee joint of
rats. Its effectiveness was reflected as reduction of edema-
tous swelling of the joint, mononuclear cell infiltration
that was dependent on soluble VCAM-1 concentration in
the blood and prevention of cartilage damage.
Conclusion
It is concluded from the results of this study that 6-shog-
aol reduced CFA induced chronic inflammatory response
in the knee joint of rats and protected the femoral carti-
lage from damage. These findings suggest that 6-shogaol
has useful anti-inflammatory properties that can be
exploited.
Methods
Experimental animals
Female Sprague-Dawley rats (weighing 200–250 g) were
used in this study. They were bred from Taconic farm
stock (USA) in the Animal Care facility of the Department
of Basic Medical Sciences, University of the West Indies.
Throughout the experimental period, the animals were
housed three per cage and kept on a 12:12-hour light-dark
cycle. They also had access to food (PMI formulab 5008,
labdiet) and water ad libitum. Procedures involving ani-
mal care and use conformed to the guidelines of the
National Research Council (USA) for the use and care of
laboratory animals (ILAR/NRC, 1996).
Induction of chronic inflammation and other treatments
The rats were anesthetized with ether to facilitate the
injection of 0.5 ml (1 mg/ml) of commercially prepared
complete Freund's adjuvant (CFA from Sigma Aldrich)
into the synovial cavity of the right knee of each rat. Note
that this was the minimum amount of the CFA prepara-
tion that produced measurable inflammatory response in
our study. After recovery from the anesthetic, the rats were
allowed to develop chronic inflammation over a period of
28 days. During this period and one day before CFA injec-
tion, each animal (in groups of 6) received a daily oral
dose (via gavage) of either 0.2 ml peanut oil (Hain Celes-
tial, USA) in the control group or 6.2 mg/Kg 6-shogaol
(Chromadex, California) in 0.2 ml peanut oil in the test
group or 2 mg/Kg indomethacin (Sigma Aldrich) which
was used as a standard drug to show the typical anti-
inflammatory effect on the edematous swelling of the
knee.
Measurement of edematous swelling of the knee
Throughout the investigation period, a flexible tape was
used in accordance with the procedure reported by Yu et
al [11] to make daily measurement of the knee circumfer-
ence at marked points. Note that in order to discount any
volume change due to injection of the 0.5 ml CFA, the
base line circumference of the knee for determination of
inflammatory response was taken thirty minutes after
injection of CFA. The measurement was done in triplicate
by a technician who was not involved in the study, and
the average of these measurements was used as the knee
circumference. The daily change in knee circumference
was determined from these measurements and compared
graphically for an indication of the effects of the treat-
ments on the magnitude of edematous swelling of the
knee.
Determination of leukocyte concentration in synovial fluid
Leukocyte concentration in the synovial fluid was deter-
mined on day 28 of the investigational period when 6-
shogaol was most effective in reducing the swelling of the
knee. The protocol used for this determination involved
anesthetization (with 0.8 ml/100 g of 15% urethane,
intraperitoneally) of each rat in the peanut oil treated
group and the 6-shogaol treated group. This was followed
by an incision of the skin overlying the anterior aspect of
the right knee and insertion of a 26 gauge hyperdermic
needle into the synovial cavity. This arrangement facili-
tated the infusion of 250 μL 0.9% saline into the synovial
cavity over a period of 2 minutes. A second hyperdermic
needle (26 gauge), which served as an outflow cannula,
was inserted into the synovial cavity approximately 3 mm
from the infusion needle. Five minutes after infusion of
all the saline, 200 μL of fluid was withdrawn from the syn-
ovial cavity over a period of two minutes. This synovial
fluid was then used in a Coulter counter (Coulter Corpo-
ration) to determine the concentrations of total leuko-
cytes, lymphocytes and monocytes/macrophages in
accordance with the procedure of Salinas [20].
Determination of soluble VCAM-1 concentration in blood 
samples
On day 28 of the investigational period, when 6-shogaol
was most effective in reducing the swelling of the knee, 2
ml of blood was taken from each rat in the peanut oil
treated group and the 6-shogaol treated group via vacu-
puncture of the heart. Each sample of blood was centri-
fuged (1500 REVS/10 mins) to obtain the separated
plasma which was stored at -20°C until it was assayed for
soluble VCAM-1. A microplate reader (MF iEmS, Labsys-
tems) was used to carry out this assay by Enzyme Immu-
noassay analysis (EIA) in accordance with the proceduresBMC Pharmacology 2006, 6:12 http://www.biomedcentral.com/1471-2210/6/12
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of the EIA kit supplied by the manufacturer (US Biologi-
cal).
Preparation of histological sections of the knee joint
After obtaining blood samples for quantification of solu-
ble VCAM-1 and withdrawal of fluid from the synovial
cavity for determination of leukocyte concentration on
day 28, each rat in the peanut oil treated group and 6-
shogaol treated group was sacrificed with an overdose of
ether. The total knee joint was removed surgically and
fixed for 4 days in 4 % formaldehyde (Mallinckrodt
Backer Inc.) followed by decalcification in formic acid
(BDH Chemicals Ltd.) according to the procedure by
Joosten et al [21]. Subsequent to these treatments of the
knee joint, it was dehydrated with progressively increasing
concentrations (70% – absolute) of alcohol (BDH Chem-
icals Ltd.) and embedded in paraffin. From each paraffin
preparation, longitudinal sections (5 μm) were cut and
then stained with either hematoxylin (Hopkin and Wil-
liams Ltd.) and eosin (BDH Chemicals Ltd) or safranin O
(Sigma Chemical Company) in accordance with the pro-
cedures described by Joosten et al [21]. Each stained sec-
tion was examined with a light microscope for damage to
the articular cartilage lining the head of the femur.
Statistical analysis
Each value was expressed as mean ± SEM, and n refers to
the number of animals used. The unpaired Student's t test
was used for making statistical comparisons of the results
between the control group and the test group, and a value
of p ≤ 0.05 was used to define statistically significant dif-
ferences. The Pearson correlation coefficient was used to
determine the relationship between the concentration of
soluble VCAM-1 and the magnitude of leukocyte infiltra-
tion in the synovial cavity.
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